Nevro Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Nevro kazanç ve gelirin sırasıyla yıllık 6.1% ve 2.4% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 7.5% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -46.8% olacağı tahmin edilmektedir.

Anahtar bilgiler

6.1%

Kazanç büyüme oranı

7.5%

EPS büyüme oranı

Medical Equipment kazanç büyümesi	17.7%
Gelir büyüme oranı	2.4%
Gelecekteki özkaynak getirisi	-46.8%
Analist kapsamı	Good
Son güncelleme	22 Oct 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Little Excitement Around Nevro Corp.'s (NYSE:NVRO) Revenues As Shares Take 34% Pounding

Aug 11

Nevro: Not Having My Back

Aug 09

Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?

Jul 16

Nevro Corp. (NYSE:NVRO) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough

May 01

Kazanç ve Gelir Büyüme Tahminleri

NYSE:NVRO - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	432	-78	-43	-28	10
12/31/2025	412	-96	-52	-37	15
12/31/2024	402	-99	-41	-27	15
6/30/2024	426	-77	-65	-56	N/A
3/31/2024	431	-83	-71	-62	N/A
12/31/2023	425	-92	-67	-59	N/A
9/30/2023	423	-102	-72	-63	N/A
6/30/2023	419	3	13	22	N/A
3/31/2023	415	2	15	24	N/A
12/31/2022	406	3	17	25	N/A
9/30/2022	395	-8	16	23	N/A
6/30/2022	388	-140	-80	-72	N/A
3/31/2022	386	-136	-75	-63	N/A
12/31/2021	387	-131	-54	-42	N/A
9/30/2021	394	-108	-28	-15	N/A
6/30/2021	409	-68	1	12	N/A
3/31/2021	363	-88	-8	0	N/A
12/31/2020	362	-83	-5	1	N/A
9/30/2020	367	-90	-29	-24	N/A
6/30/2020	358	-98	-43	-39	N/A
3/31/2020	396	-84	-37	-34	N/A
12/31/2019	390	-104	-54	-50	N/A
9/30/2019	384	-100	-34	-32	N/A
6/30/2019	379	-93	-37	-34	N/A
3/31/2019	382	-76	-25	-21	N/A
12/31/2018	387	-49	-14	-6	N/A
9/30/2018	377	-44	-23	-13	N/A
6/30/2018	364	-39	-11	-2	N/A
3/31/2018	346	-40	N/A	-7	N/A
12/31/2017	327	-37	N/A	-14	N/A
9/30/2017	299	-42	N/A	-27	N/A
6/30/2017	278	-40	N/A	-35	N/A
3/31/2017	255	-37	N/A	-42	N/A
12/31/2016	229	-32	N/A	-59	N/A
9/30/2016	191	-36	N/A	-73	N/A
6/30/2016	146	-52	N/A	-101	N/A
3/31/2016	102	-63	N/A	-114	N/A
12/31/2015	70	-67	N/A	-100	N/A
9/30/2015	46	-62	N/A	-79	N/A
6/30/2015	39	-50	N/A	-57	N/A
3/31/2015	36	-38	N/A	-40	N/A
12/31/2014	33	-31	N/A	-31	N/A
9/30/2014	29	-29	N/A	-27	N/A
6/30/2014	27	-26	N/A	-24	N/A
3/31/2014	25	-26	N/A	-22	N/A
12/31/2013	24	-26	N/A	-21	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: NVRO önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: NVRO önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: NVRO önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: NVRO şirketinin gelirinin (yıllık 2.4% ) US pazarından (yıllık 8.9% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: NVRO şirketinin gelirinin (yıllık 2.4% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: NVRO 3 yıl içinde kârsız olması bekleniyor.

Nevro Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus EPS estimates fall by 21%

Price target decreased by 25% to US$11.07

Nevro Revises Earnings Guidance for the Full Year 2024

Consensus EPS estimates upgraded to US$2.31 loss

Price target decreased by 12% to US$16.63

Nevro Corp. Provides Earnings Guidance for the Second Quarter Ending June 30, 2024 and Revises Earnings Guidance for the Full Year Ending December 31, 2024

Recent updates

Nevro Corp. Announces New Data Demonstrates Long-Term Improvements in Pain Intensity with Nevro's High-Frequency Spinal Cord Stimulation Therapy

Nevro Corp. to Report Q3, 2024 Results on Nov 11, 2024

Consensus EPS estimates fall by 21%

Little Excitement Around Nevro Corp.'s (NYSE:NVRO) Revenues As Shares Take 34% Pounding

Nevro: Not Having My Back

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 25% to US$11.07

Nevro Revises Earnings Guidance for the Full Year 2024

Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?

Nevro Corp. to Report Q2, 2024 Results on Aug 06, 2024

Consensus EPS estimates upgraded to US$2.31 loss

Price target decreased by 12% to US$16.63

Nevro Corp. Provides Earnings Guidance for the Second Quarter Ending June 30, 2024 and Revises Earnings Guidance for the Full Year Ending December 31, 2024

Nevro Corp. (NYSE:NVRO) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough

Nevro Corp. to Report Q1, 2024 Results on May 07, 2024

New minor risk - Shareholder dilution

Nevro Corp., Annual General Meeting, May 23, 2024

Price target decreased by 9.5% to US$19.40

Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?

Full year 2023 earnings: EPS exceeds analyst expectations

Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2024

Nevro Corp. to Report Q4, 2023 Results on Feb 21, 2024

There Is A Reason Nevro Corp.'s (NYSE:NVRO) Price Is Undemanding

Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain

Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?

Nevro Corp. Increases Revenue Guidance for the Full-Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.2% to US$26.37

New major risk - Revenue and earnings growth

Nevro Corp. to Report Q3, 2023 Results on Nov 01, 2023

Nevro: Economic Realities Too Deep To Ignore, Downgrade To Hold

Nevro Corp. Announces New 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic Neuropathy

Nevro Announces Launch of HFX Connect in Europe and CE Marking of Expanded Labelling for the HFX SCS system

Consensus EPS estimates fall by 16%

Nevro Corp. Revises Earnings Guidance for the Full-Year 2023

New minor risk - Shareholder dilution

Price target decreased by 23% to US$28.80

Nevro (NYSE:NVRO) Has Debt But No Earnings; Should You Worry?

Price target decreased by 8.5% to US$37.57

Independent Director recently bought US$172k worth of stock

Price target decreased by 8.5% to US$38.43

Nevro Corp. Announces Executive Changes

Nevro Corp. to Report Q2, 2023 Results on Aug 01, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Independent Lead Director exercised options to buy US$2.9m worth of stock.

Investors Shouldn't Be Too Comfortable With Nevro's (NYSE:NVRO) Robust Earnings

Nevro falls to 52-week low; down ~49% over last year

Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Nevro: Treating Patient Back Pains, Causing Shareholder Back Pains

Nevro Corp. to Highlight New Clinical Evidence at the 2023 North American Neuromodulation Society 26th Annual Meeting

Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?

Consensus forecasts updated

Nevro Corp. to Report Q4, 2022 Results on Feb 16, 2023

Nevro: Opportunity Overshadowed By Weaknesses

Price target decreased to US$47.73

Consensus forecasts updated

Price target decreased to US$50.36

Nevro Corp. Updates Earnings Guidance for the Year Ending December 31, 2022

Boston Scientific drives rival Nevro lower after remarks on neuromodulation

Price target decreased to US$53.91

Nevro Corp. Announces FDA Approval of HFX iQ™ Spinal Cord Stimulation System to Personalize the Treatment of Chronic Pain

Nevro's Senza spinal cord stimulation system for chronic pain gets FDA approval

Nevro Corp. to Report Q3, 2022 Results on Nov 02, 2022

Nevro gets FDA approval for Costa Rica manufacturing operations

Nevro Corp. Announces American Association of Clinical Endocrinology Clinical Practice Guideline Has Been Updated to Include High-Frequency 10 kHz Spinal Cord Stimulation to Treat Painful Diabetic Neuropathy

Is Nevro (NYSE:NVRO) Weighed On By Its Debt Load?

Nevro Corp. Announces Executive Changes

Nevro: Niche Operator In Neuropathy, Reluctant Hold On Valuation